CEACAM1-induced drugs enhance chemosensitivity of Hepatoblastoma

Research Project

Project/Area Number	26861486
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Pediatric surgery
Research Institution	Wakayama Medical University
Principal Investigator	Mitani Yasuyuki 和歌山県立医科大学, 医学部, 学内助教 (40612106)
Project Period (FY)	2014-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000) Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000) Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords	肝芽腫 / CEACAM1 / CDDP
Outline of Final Research Achievements	In a clinical study, CEACAM1 expression suggest the benign prognostic factor in hepatoblastoma. Suppression of CEACAM1 expression in hepatblastoma cell lines reduces the effect of cancer drugs (CDDP). All-trans retinoic acid (ATRA) induces the CEACAM1 expression in hepatblastomat cell lines, and combination with ATRA and CDDP enhance the effect of CDDP. CEACAM1 short isoform expression in hepatblastoma cell lines is associated with chemosensitivity.